DNA Therapeutics does not have NIH  ("Not Invented Here") syndrome. It is open to collaborations in research and development in order to expand continuously its network with the primary objectives of accessing external resources, incorporating expertise and knowledge so as to reduce time to market and enrich its pipeline.

Research

DNA Therapeutics acts as a life science technology integrator, specialized in translational research, mainly through technology transfer from renowned research institutions, by implementing the "from bench to bedside and back" concept. The basic research aimed at deciphering the mechanisms of action and the specificity of siDNA molecules is performed in the Institutions where the initial discoveries took place: the Institut Curie, CNRS, INSERM & MNHN. One of DNA Therapeutics’ strong assets is its ability to work closely with some of the world’s leading research laboratories in oncology and genetics in Europe and in North America. These partnerships are formalized under collaborative research agreements in order to enhance our translational research franchise. It will also benefit the top tier clinical expertise from the clinical investigation centers linked to these academic institutions.